PCSK9 RNAi Therapy for Sustained LDL-C Reduction in ASCVD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for reducing low density lipoprotein cholesterol (LDL-C) levels, such as statins, are inadequate for many individuals at risk for atherosclerotic cardiovascular disease (ASCVD), and monoclonal antibodies targeting PCSK9 have a short duration of effect and significant administration burdens.
Innovation Solution
The use of RNA interference (RNAi) agents, specifically double-stranded ribonucleic acids with defined nucleotide sequences, to inhibit PCSK9 synthesis and lower LDL-C levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to block PCSK9, then LDL-C levels are reduced, but the duration of effect is short and administration burden increases
Solution Approach 1:
The patent replaces monoclonal antibody therapy (biological mechanism) with RNA interference technology (molecular mechanism). The RNAi agent specifically targets PCSK9 mRNA to inhibit protein synthesis, achieving sustained LDL-C reduction without the short duration limitations of monoclonal antibodies. This substitution of therapeutic mechanism resolves the contradiction between efficacy reliability and duration of action.
Solution Approach 2:
The patent changes the therapeutic parameter from protein-based monoclonal antibodies to nucleic acid-based RNAi agents. This parameter change enables prolonged duration of effect because RNAi agents can sustain gene silencing over time, addressing the short duration limitation while maintaining reliable LDL-C reduction through specific PCSK9 mRNA targeting.
2Reliability
If monoclonal antibodies are used to block PCSK9, then LDL-C levels are reduced, but administration burden increases
Solution Approach 1:
The patent substitutes monoclonal antibody administration (requiring frequent injections) with RNAi agent administration (enabling less frequent dosing). The RNAi mechanism of inhibiting PCSK9 mRNA translation provides sustained effect that reduces administration frequency and burden while maintaining reliable LDL-C lowering efficacy.
3Reliability
If statins are used to lower lipid levels, then some LDL-C reduction is achieved, but many at-risk subjects continue to have elevated LDL-C levels
Solution Approach 1:
The patent introduces RNAi agents as an intermediary therapeutic approach between statins and PCSK9. The RNAi agent specifically targets PCSK9 mRNA, providing a mechanism that directly reduces PCSK9 protein levels and enhances LDL-C lowering beyond what statins alone can achieve, thereby addressing insufficient LDL-C reduction in at-risk subjects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively reduce LDL-C levels by over 20% and maintain the reduction for several months, thereby potentially preventing cardiovascular events and reducing ASCVD risk.
Implementation Method 1
The present invention relates to the use of an RNA interference (RNAi) agent that inhibits the synthesis of PCSK9
Data Source
AI summary
Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent. Also, a method of preventing development of atherosclerotic cardiovascular disease in a subject involving administering to the subject a prophylactically effective amount of an RNAi agent. Further, a method of treating a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent involving administering to the subject a therapeutically effective amount of an RNAi agent.